Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

Masatoshi Sakurai, Taku Kikuchi, Daiki Karigane, Hidenori Kasahara, Eri Matsuki, Risa Hashida, Yusuke Yamane, Ryohei Abe, Yuya Koda, Takaaki Toyama, Jun Kato, Takayuki Shimizu, Yuta Yokoyama, Sayo Suzuki, Tomonori Nakamura, Shinichiro Okamoto, Takehiko Mori

Research output: Contribution to journalArticle

Abstract

Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

Original languageEnglish
Pages (from-to)292-298
Number of pages7
JournalInternational journal of hematology
Volume109
Issue number3
DOIs
Publication statusPublished - 2019 Mar 20

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anemia
Hemoglobins
Glomerular Filtration Rate
Kidney
Therapeutics
Leukemia, Myeloid, Chronic Phase
Erythropoietin
Imatinib Mesylate
Multivariate Analysis
Clinical Trials
Serum

Keywords

  • Anemia
  • Chronic myelogenous leukemia
  • Imatinib
  • Renal dysfunction

ASJC Scopus subject areas

  • Hematology

Cite this

Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. / Sakurai, Masatoshi; Kikuchi, Taku; Karigane, Daiki; Kasahara, Hidenori; Matsuki, Eri; Hashida, Risa; Yamane, Yusuke; Abe, Ryohei; Koda, Yuya; Toyama, Takaaki; Kato, Jun; Shimizu, Takayuki; Yokoyama, Yuta; Suzuki, Sayo; Nakamura, Tomonori; Okamoto, Shinichiro; Mori, Takehiko.

In: International journal of hematology, Vol. 109, No. 3, 20.03.2019, p. 292-298.

Research output: Contribution to journalArticle

Sakurai, Masatoshi ; Kikuchi, Taku ; Karigane, Daiki ; Kasahara, Hidenori ; Matsuki, Eri ; Hashida, Risa ; Yamane, Yusuke ; Abe, Ryohei ; Koda, Yuya ; Toyama, Takaaki ; Kato, Jun ; Shimizu, Takayuki ; Yokoyama, Yuta ; Suzuki, Sayo ; Nakamura, Tomonori ; Okamoto, Shinichiro ; Mori, Takehiko. / Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. In: International journal of hematology. 2019 ; Vol. 109, No. 3. pp. 292-298.
@article{c3c2b10651b14a459f45596fd0bd6c24,
title = "Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia",
abstract = "Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.",
keywords = "Anemia, Chronic myelogenous leukemia, Imatinib, Renal dysfunction",
author = "Masatoshi Sakurai and Taku Kikuchi and Daiki Karigane and Hidenori Kasahara and Eri Matsuki and Risa Hashida and Yusuke Yamane and Ryohei Abe and Yuya Koda and Takaaki Toyama and Jun Kato and Takayuki Shimizu and Yuta Yokoyama and Sayo Suzuki and Tomonori Nakamura and Shinichiro Okamoto and Takehiko Mori",
year = "2019",
month = "3",
day = "20",
doi = "10.1007/s12185-019-02596-z",
language = "English",
volume = "109",
pages = "292--298",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia

AU - Sakurai, Masatoshi

AU - Kikuchi, Taku

AU - Karigane, Daiki

AU - Kasahara, Hidenori

AU - Matsuki, Eri

AU - Hashida, Risa

AU - Yamane, Yusuke

AU - Abe, Ryohei

AU - Koda, Yuya

AU - Toyama, Takaaki

AU - Kato, Jun

AU - Shimizu, Takayuki

AU - Yokoyama, Yuta

AU - Suzuki, Sayo

AU - Nakamura, Tomonori

AU - Okamoto, Shinichiro

AU - Mori, Takehiko

PY - 2019/3/20

Y1 - 2019/3/20

N2 - Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

AB - Knowledge of the toxicity profile of long-term treatment with imatinib is limited. In the present study, we sought to evaluate renal function and hemoglobin levels during long-term imatinib treatment. Eighty-two patients with chronic myelogenous leukemia in chronic phase who had been on imatinib for over 5 years were retrospectively analyzed. The mean estimated glomerular filtration rate (eGFR) was significantly decreased over 5 years (77 ± 17 to 62 ± 14 ml/min/1.73m², P < 0.001). Higher age and lower eGFR value at initiation of imatinib were significantly associated with development of renal dysfunction by multivariate analyses. Mean hemoglobin levels also significantly decreased over the 5-year period (12.9 ± 1.7 to 12.4 ± 1.3 g/dl, P < 0.01). The rate of decrease in eGFR correlated significantly with hemoglobin levels (correlation coefficient = − 0.249, P < 0.05). Serum erythropoietin (EPO) levels did not increase in 16 patients with both renal dysfunction and anemia (median, 31.9 mIU/ml). In patients who participated in a clinical trial of imatinib discontinuation, mean eGFR (50.0 ± 6.5 to 56.0 ± 10.2 ml/min/1.73m², P < 0.05) and hemoglobin levels (12.0 ± 1.7 to 14.0 ± 1.6 g/dl, P < 0.01) improved significantly at 1 year after discontinuation. These findings suggest that long-term imatinib results in a partially reversible continuous decline in renal function and decreased hemoglobin levels.

KW - Anemia

KW - Chronic myelogenous leukemia

KW - Imatinib

KW - Renal dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85062087606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062087606&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02596-z

DO - 10.1007/s12185-019-02596-z

M3 - Article

C2 - 30680668

AN - SCOPUS:85062087606

VL - 109

SP - 292

EP - 298

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 3

ER -